Clinical Trial Update: Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the efficacy and safety of combining IBI310 with sintilimab in patients with advanced hepatocellular carcinoma has completed, reporti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED